x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

22:50

138. Back to Basics - Adjuvant CDK4/6 inhibitors in...

Oncology for the Inquisitive Mind ·

2024/11/30

Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improvements are much harder to substantiate with the effect treatments currently on the market, but there is promise. This week, on our Back to Basics episode, Michael and Josh look at the role of abemaciclib and ribociclib in the adjuvant setting in patients with high-risk early breast cancer. Both of these

en

26:40

137. Back to Basics - High Risk Breast Cancer

Oncology for the Inquisitive Mind ·

2024/11/23

Breast Cancer is complex, as are the treatment options that clinicians and patients must traverse. Stage III breast cancer has up to a 57% chance of recurring up to 20 years after diagnosis. Josh and Michael look at one of the practice-changing papers that tried to address how to manage high-risk patients. This study is called Soft and Text. It asked if adding ovarian suppression to aromatase inhibitors was better than ovarian suppression with selective estrogen receptor modulators (SERMs) to reduce

en

39:06

136. Evolving landscape of Genitourinary Cancers...

Oncology for the Inquisitive Mind ·

2024/11/16

Prof Enrique Grande, a medical oncologist from Madrid, Spain, is our guest on Oncology for the Inquisitive Mind this week. Enrique is not your average oncologist nor your average podcast guest with a fascinating back story, a varied career and the charisma and wisdom to match!Enrique has worked in all facets of oncology, including industry and is helping transform how patients access oncology care in Spain. He is the director of the Medical Oncology Program and Clinical Research Lead at the MD

en

28:24

135. ESMO 2024 - Breast Cancer with Dr Adam Brufsky

Oncology for the Inquisitive Mind ·

2024/11/09

In our final ESMO 2024 analysis this week, we bring back Dr. Adam Brufsky, "a giant among men (and women)" in breast cancer research and management. He discusses the field, the pivotal updates in ESMO, and what this means for patients. He also explores many of the unanswered questions.Links to studies discussed in this episode (subscription may be required):DESTINYBREAST012KEYNOTE522Many other pearls of wisdom - so tune in!For more episodes, resources and blog posts, visit

en

30:15

134. ESMO 2024 - Lung Cancer with Dr Ned McNamee

Oncology for the Inquisitive Mind ·

2024/11/02

Lung cancer treatment has changed seismically since 2018 and the NEJM publication of Keynote 189. This week, we have Dr. Ned Mcnamee on the show to give us his highlights of lung cancer updates from ESMO 2024. He explores the resectable lung cancer space with Checkmate-77T; crosses the ADRIATIC trial in patients with limited-stage small cell lung cancer, and brings in a home run with an updated LAURA trial mention (osimertinib after definitive chemoradiotherapy)Links to studies discussed in this

en

31:12

133. ESMO 2024 - Genitourinary Cancers with Prof...

Oncology for the Inquisitive Mind ·

2024/10/26

ESMO 2024 was the year genitourinary cancer took front and centre stage with many exciting updates, trials, and tribulations. This week, OFTIM brings their greatest champion back to dive deep into the changes that will impact our patients and their families, the NCCN guidelines, and how we practice medicine. Unfortunately, the heavyweight champion boxer was unavailable, but we got the next best thing - Prof Anthony Joshua from St Vincent's Health and The Garvan Institute of Medical Research. This

en

18:17

132. ESMO 2024 - Colorectal Cancer with Dr Geoffrey...

Oncology for the Inquisitive Mind ·

2024/10/19

With ESMO 24 firmly in the rearview mirror, the dust settling, and the end of the year closing in, Michael and Josh take one final look at the trials that may change practice, direct research, or are just generally interesting. This week, we interviewed Dr Geoffrey Chong, a medical oncologist specialising in gastrointestinal cancers who currently holds appointments at the Olivia Newton-John Cancer Wellness and Research Centre and the Northern Hospital.Enjoy!Links to studies discussed in this episode

en

37:07

131. ESMO 2024 - Plenary Special

Oncology for the Inquisitive Mind ·

2024/09/18

We have finally come to the end of ESMO 2024, and as is now tradition, Michael and Josh conclude their epic journey with a special episode highlighting their absolute favourite practice-changing selections from the Plenary Sessions. As always, ESMO brought a selection of wonderful studies that truly deserve the title "practice changing." As always, a huge thanks to everyone who joined us on this amazing journey. It has been a wonderful experience to attend a major international conference for the

en

32:25

130. ESMO 2024 - Day 4

Oncology for the Inquisitive Mind ·

2024/09/17

The end of the road approaches, and ESMO 2024 will soon be in the rearview mirror. However, each new day brings new, incredible advances in the treatment of cancer. Today, Josh and Michael dive into biomarker analyses, overall survival updates and new antibody-drug conjugates galore. Listen on for our penultimate summary of ESMO.Studies discussed in this episode:Biomarker analysis of PEACE-1ARANOTESTAMPEDE - Addition of MetforminClinical activity of BMS-986365, dual androgen receptor ligand-directed

en

22:45

129. ESMO 2024 - Day 3

Oncology for the Inquisitive Mind ·

2024/09/16

Day three of the European Society of Medical Oncology Congress had many exciting and potentially practice-changing trials in the genitourinary space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy.They look at biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma.Links to studies discussed in this

en

30:06

128. ESMO 2024 - Day 2

Oncology for the Inquisitive Mind ·

2024/09/15

Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the European Society of Medical Oncology. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supportive care to head and neck cancer and so many other fascinating studies in between. Read on to listen

en

24:06

127. ESMO 2024 - Day 1

Oncology for the Inquisitive Mind ·

2024/09/14

The European Society of Medical Oncology Congress has begun, and Michael and Josh are on the ground, bringing you breaking studies and heartbreaks along with some important updates in the science and art of medical oncology.Michael and Josh cover a range of tumour types on day one, a slight deviation from our regular coverage. They look at hepatocellular carcinoma, renal cancers, and breast cancer, an eclectic but exciting mix of cancer types.Michael investigates HCC treatment with iparomlimab and

en

41:12

126. Ocular Melanoma and Prostate Cancer with A/Prof...

Oncology for the Inquisitive Mind ·

2024/08/24

Oncology for the Inquisitive Mind has been privileged to interview some truly brilliant specialists, and this week's guest is no exception. Professor Anthony Joshua is the Head of Oncology at the Kinghorn Cancer Centre and St Vincent's Health in Sydney. He is a globally recognised expert in genitourinary cancers and melanoma, with a special interest in ocular melanoma. Professor Joshua completed his PhD in prostatic carcinogenesis under the supervision of Dr Jeremy Squire and a clinical fellowship

en

37:29

125. Spotlight - Biotech ImmVirX with Dr Malcolm...

Oncology for the Inquisitive Mind ·

2024/08/17

Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used in melanoma and other malignancies.ImmVirx has developed a proprietary bio-selected RNA virus that is

en

30:40

124. Metastatic HER2- positive breast cancer

Oncology for the Inquisitive Mind ·

2024/08/10

Metastatic HER2-positive breast cancer continues to dominate headlines, and new therapeutic options continue to be found for those afflicted with the disease. Before trastuzumab (anti-HER2 therapy), the overall survival for this cohort of patients was less than two years. As technology and treatments changed, it can boast an extended survival well beyond five years in numerous studies, with many patients responding far more than that number.This week, we will discuss two exciting and pioneering

en

25:51

123. Spotlight: MARIPOSA for EGFRmut Lung Cancer

Oncology for the Inquisitive Mind ·

2024/08/03

The discovery of EGFR as a driver mutation and the development of medications to take advantage of this mutation changed the treatment of non-small cell lung cancer (NSCLC) forever. Not only did it vastly improve outcomes for patients with this subset of cancers, it opened the door for the likes of alectinib, lorlatinib and sotorasib to carve out niches for their own driver mutations. However, the treatment remains imperfect and people much smarter than Josh and Michael have been hard at work trying

en

43:59

122. Palliative Care with Dr Janet Abrahm

Oncology for the Inquisitive Mind ·

2024/07/27

It is rare on any show to be able to interview a true pioneer. On today's episode of Oncology for the Inquisitive Mind, we have the privilege of interviewing Dr Janet Abrahm, a pioneer in every sense of the word. An internist with over 20 years experience, Dr Abrahm was one of the founders and earliest proponents of palliative care in the United States. A staff specialist at the Dana Farber Cancer Institute, she is board-certified in Hematology, Hospice and Palliative Medicine, Internal Medicine,

en

36:04

121. Dr Elias Chandran, the NCI and urothelial...

Oncology for the Inquisitive Mind ·

2024/07/20

This week, we interview Dr Elias Chandran, a medical oncologist and emerging research juggernaut who is an assistant research physician at the National Cancer Institute in Bethesda, Maryland. His focus is on genitourinary cancer, and he has recently published a pivotal systematic review and meta-analysis titled "Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis".Dr Chandran is the epitome of a resilient clinician, having

en

42:11

137. Artificial Intelligence with Professor Meredith...

Oncology for the Inquisitive Mind ·

2024/07/13

Today, Michael and Josh interview Professor Meredith Broussard, author of More than a Glitch and data journalist at the Arthur L Carter Journalism Institute of New York University. Meredith has had an exceptionally versatile career, previously having worked as a software developer for MIT Media Lab and a former features editor at the Philadelphia Inquirer. She is also the author of numerous other books, including Confronting Race, Gender, and Ability Bias in Tech” and “Artificial Unintelligence. She

en

52:17

119. ASCO 2024 - Plenary Session

Oncology for the Inquisitive Mind ·

2024/06/17

"Here at last, at the edge of the sea, comes the end of our Fellowship." So said Gandalf the White at the conclusion of J.R.R Tolkien's epic The Lord of the Rings. Today, Josh and Michael have a no less epic conclusion to their own adventure, that of ASCO 2024. Over the last fifteen days, our intrepid hosts have journeyed across the world of medical oncology, from the highs of colorectal, breast and lung cancer to the dark days of central nervous system tumours. As is our tradition, we end our

en

195 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Podcasts Archives - Extreme Health Radio

Justin Stellman

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Good Sleep: Positive Affirmations

Optimal Living Daily | Sleepy Meditation

Johannes Hansen Podcast

Johannes Hansen